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Objectives: To characterize prescribing error interventions documented by pharmacists in four 
pharmacies in a primary health care service in Qatar.
Methods: The study was conducted in a primary health care service in the State of Qatar in 
the period from January to March 2008. Pharmacists in four clinics within the service used 
online, integrated health care software to document all clinical interventions made. Documented 
information included: patient’s age and gender, drug therapy details, the intervention’s details, 
its category, and its outcome. Interventions were categorized according to the Pharmaceutical 
Care Network Europe Classification of drug-related problems (DRP).
Results: The number of patients who had their prescriptions intercepted were 589 (0.71% of the 
total 82,800 prescriptions received). The intercepted prescriptions generated 890 DRP-related 
interventions (an average of 1.9% DRPs identified across the four clinics). Fifty-four percent 
of all interventions were classified as drug choice problems, and 42% had safety problems 
(dose too high, potential significant interaction). The prescriber accepted the intervention in 
53% of all interventions, and the treatment was changed accordingly. Interventions as a result 
of transcription errors, legality and formulary issues were eliminated from this study through 
the use of computerized physician order entry (CPOE).
Conclusions: Documenting and analyzing interventions should be a routine activity in pharmacy 
practice setting in primary health care services. Educational outreach visits and other strategies 
can improve prescribing practices and enhance patient safety.
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Introduction
Pharmacists are gradually extending their professional roles, slowly shifting their 
attention from the passive dispensing of medications to actively caring for their patients. 
This shift of focus has occurred over many years with different degrees of success and 
intensity. The impact of the ideals of pharmaceutical care on the change of pharmacy 
and on its new ethical paradigm cannot be underestimated.1 However, the publication 
in 2000 of the report To Err Is Human: Building a safer health system and others such 
as An Organization with a Memory and A Spoonful of Sugar contributed significantly 
to drawing attention to the problems associated with pharmacotherapy and stimulated 
research and discussion about patient safety issues.2–4 A key role of pharmacists in ensur-
ing the safety of medications prescribed and dispensed to patients emerged.1At around the 
same period of time, Johnson and Bootman published a landmark article in which they 
estimated the annual cost of adverse effects of ambulatory drug use in the United States 
to be US$76 billion, equaling the annual cost for procuring drugs. The Medical Protection Drug, Healthcare and Patient Safety 2009:1 74
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Society in the UK estimates that medication errors account for 
approximately 20% of all clinical negligence claims against 
doctors in both primary and secondary care.5 These significant 
events helped to bring both the issue of patient safety and the 
potential role of the pharmacist in enhancing patient safety 
to the forefront.6
Clinicians are not good at following recommendations 
for best practice and implementing guidelines resulting in 
underuse, overuse, and misuse of drugs.7
Pharmacists are placed in an excellent position to promote 
rational use of medicines (ie, prescribing, dispensing, and 
use). Rational use of medicines requires that patients receive 
medications appropriate to their clinical needs, in doses that 
meet their individual requirements, for an adequate period of 
time, and at the lowest cost to them and/or their community.8 
The positioning of pharmacists at crucial stages in the drug 
use process (be it in an outpatient dispensary, a community 
pharmacy, or beside the patient’s bed in a hospital after the 
drug has been prescribed) allow them to play a vital role in 
rationalizing drug use through identifying, preventing, and 
resolving drug-related problems (DRPs). Medication errors 
(defined as any preventable event that may cause or lead to 
inappropriate medication use or to patient harm) are the most 
prevalent form of DRPs, and prescribing errors are the most 
important source of medication errors.9
Since the 1970s, medication error research started to 
extend to nonacute care settings, including nursing homes, 
outpatient pharmacies, and special patient populations. 
The term “medication misadventuring” was introduced by 
Manasse who made a strong argument for increased public 
policy attention to this problem.10 Research that addresses 
prescribing errors has the potential to influence the percep-
tion of, and attitude towards, medication errors to produce 
fundamental changes within the pharmacy, nursing, medical 
staff, and in the environment they work within.
The literature on prescribing errors is gaining momentum, 
and the data so far suggests that the problem is not limited to 
any specific health care environment or defined practice setting. 
For example, a UK community pharmacy study reported 0.7% 
prescribing errors identified, and around 28% of the identified 
problems could have resulted in patient harm.9 In the hospital 
setting, pharmacists’ interventions were demonstrated in ini-
tiating changes to hospitalized patient management which led 
to cost savings relating to length of stay, readmission, drugs, 
medical procedures, and laboratory monitoring.11
Technology has a promising role in reducing adverse 
drug events. It has been reported that computerized decision 
support systems (CDSS) reduced the incidence of over 
dosage, adverse reactions, and the length of hospital stay.12 
CDSS were also effective in changing the class of drug 
prescribed, increasing generic prescribing, and improving 
activities related to medication management.
Other prescribing error reduction strategies include 
electronic prescribing (EP) and PDA-based documentation 
and use. These proved successful in collecting data on DRPs 
and documenting pharmacist interventions.13 Electronic 
prescribing minimized and sometimes eliminated errors of 
omission (incomplete scripts), such as missing important 
patient or prescriber’s information. These tools also minimized 
the occurrence of drug-drug interactions, dosage problems, 
and inconveniences caused by prescribing a medication that 
was out of stock. In hospitals, information technology (IT) has 
proved cost-effective and even reduced mortality rates.14
Interventions that are most effective for influencing pre-
scribing practice include feedback, reminders, educational 
outreach visits, and patient-mediated interventions.15
Grindrod and colleagues suggested that for pharmacists 
to positively impact prescribing practices they should focus 
on these strategies rather than relying primarily on passive 
didactics or dissemination of guidelines.16
Despite the evidence published so far on prescribing errors, 
there is still a paucity of research reporting the role of pharma-
cists in identifying these errors and the prevalence of near-miss 
incidents in the prescribing process. Indeed, we could find no 
previously published work to document and bench-mark the 
problem of prescribing errors or the role played by pharmacists 
in identifying these errors in primary health care in Qatar, or 
other countries of the Arabian Gulf region. We believe it is of 
paramount importance that all pharmacists positioned at the 
frontline of the drug-use process promote effective report-
ing and information sharing on the number, types, causes, 
and consequences of prescribing errors. This could facilitate 
research that assists in better understanding the root cause 
of prescribing errors and the development of appropriate 
process control measures to minimize them. The aim of this 
study was therefore to characterize and analyze interventions 
documented by pharmacists in outpatient pharmacies of 
a primary health care service in Qatar.
Methods
This prospective, descriptive research project was conducted 
in four primary health care clinics (coded A, B, C, and D for 
the purpose of this study) within a primary health care service 
in the capital city of the State of Qatar, in the period from 
January to March 2008. Each of these clinics is supported 
by an embedded pharmacy team composed of a senior Drug, Healthcare and Patient Safety 2009:1 75
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pharmacist with wide administrative duties and a number 
of pharmacists and pharmacy assistants (Table 1). Prior 
to data collection, pharmacists in the four clinics attended 
two orientation workshops covering the concepts of DRPs, 
pharmacy interventions, categorizing intervention, and the 
documentation process.
Pharmacists used online integrated health care software 
(TrakCare®; InterSystems, Cambridge, MA, USA) to 
document all interventions made. Documented information 
included: patient’s age and gender, drug therapy details, the 
intervention details, its category, and its outcome (at pre-
scriber level; at patient level; at drug level). Each intervention 
made was communicated to the respective prescriber by the 
intervening pharmacist in person or by phone. Interven-
tion data and their outcomes were retrieved weekly from 
the respective clinics’ software and entered by a research 
team member in a dedicated Excel spreadsheet (Microsoft 
Corp., Redmond, WA, USA) for preliminary analysis and 
data cleaning. The data was then exported to SPSS software 
(version 17; SPSS Inc., Chicago, IL, USA) for final analysis. 
All interventions and their outcomes were reviewed later 
by two members from the research team (Abdullah Adam, 
and Nadir Kheir), who also categorized the intervention as 
per the Pharmaceutical Care Network of Europe (PCNE) 
classifications in broad DRP classes. The outcome of the 
intervention (on prescriber or patient level) was recorded in the 
pharmacy’s software (as intervention; a) approved and treat-
ment changed, b) approved and no treatment was changed, 
c) rejected, information only. Medication counseling, referral 
made, written information provided was also noted).
Data analysis
Each intervention was considered a potential DRP and 
was categorized using an adaptation of the Pharmaceutical 
Care Network Europe Classification of DRPs (revised 
01-05-06 V5.01) (Table 2).17 Means and percentages were 
calculated for the numbers and outcomes of interventions, 
including other variables where applicable. Correlations 
were expressed as Pearson’s correlation coefficient (r) and 
statistical significance was set at P  0.05.
The data were exported from the clinics’ integrated health 
care software into the study Excel spreadsheet and then to 
the SPSS software for analysis.
The study looked at interventions made without reference 
to the identities of specific patient, doctor, or pharmacist. 
The study was approved by the Department of Medical 
Services at the primary health care facility in Doha, no 
direct patient involvement (eg, interviews) were involved 
and, no personal details were published.
Definitions
1.  Our working definition for a pharmacy intervention was: 
‘any contact made by a pharmacist during the dispensing 
process with a prescriber or a patient and that was aimed 
at rationalizing drug prescribing or use’.
2.  We adopted the PCNE’s definition of DRPs which states 
that a DRP is ‘an event or circumstance involving drug 
therapy that actually or potentially interferes with desired 
health outcomes.17
Furthermore, we considered a prescribing error as any 
prescribing decision which results, or had the potential to 
result in, an unintentional significant reduction in the prob-
ability of treatment being timely and effective, or an increase 
in the risk of patient harm.
Table 1 Demographics of the clinics
Clinic No of shifts Pharmacy staff Average 
Rx/day
A 2 Four pharmacists, one 
assistant pharmacist
150
B 2 12 pharmacists, one 
assistant pharmacist
450
c 2 Six pharmacists, one 
assistant pharmacist
280
D 2 Four pharmacists, one 
assistant pharmacist
270
Notes:   All pharmacies had two shifts per working day except the weekend (Saturday 
where there was 1 shift only). Fridays are public holidays. clinic B has several other 
smaller associated pharmacy dispensaries distributed at different locations and inter-
vention data was collected in all its branches.
Table 2 The pharmaceutical care network Europe classification 
of DRPs
Category Subcategory
Dosing problem
Drug interactions
Safety problem Drug not administered (drug use problem)
Adverse drug reaction
Wrong drug
inappropriate drug
inappropriate form
Drug choice problem Duplicate therapy
contraindication
no indication
no drug but clear indication
Other problems need for education, therapy failure, 
dissatisfaction with treatmentDrug, Healthcare and Patient Safety 2009:1 76
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Results
Of a total of 82,800 patients presenting with prescriptions in 
a three-month period, there were 594 patients (Table 3) whose 
prescriptions were intercepted for suspected errors (0.72%). 
The total number of DRP-related interventions made in the 
study period was 890 interventions. Table 4 provides the dis-
tribution of all interventions across clinics (total prescriptions 
dispensed, number and percentage of intervention per clinic 
and in total). 10.8% of the total prescriptions intercepted were 
for children who were aged five years or younger and 3.5% 
were for children who were aged between six to 12 years. 
Prescriptions for patients who were 60 years or older were 
3% of the total prescriptions intercepted, and the majority 
(83% of the total) was for patients whose ages lie between 
13 and 59 years. Overall, the percentage of errors intercepted 
ranged from 0.4 to 1.9 % of the total prescriptions dispensed. 
The mean across all clinics was 1.7%.
Figure 1 shows the classes of interventions made based 
based upon the PCNE classification of DRPs. Over half of all 
errors were related to drug choice problems, followed by drug 
safety problems. When drug choice problems were further 
analyzed (Figure 2), prescribing inappropriate drug therapy 
contributed 39% of the total, followed closely by duplicate 
therapy (32%). In interventions classified as safety problems, 
51% of the interventions (ie, 188 interventions from a total 
of 363) were related to dosing errors (Figure 3).
Intervention outcomes were categorized using the 
PCNE classification. At the prescriber’s level, 53% of all 
interventions made across the four clinics were accepted 
and treatment modified. The outcome of the interventions 
that were accepted by the prescriber at the drug level are 
summarized in Figure 4. In 35% of the interventions, a dose 
was changed, and in 20% the drug was changed.
At the patient level, written information was provided 
to the patient in over 60% of the interventions made, and 
medication counseling (over and above the routine instruc-
tions given at the dispensing window) took place in 24% 
of all interventions in this category (Figure 5). At the drug 
level, dosage change was the most documented outcome 
(Figure 6).
Discussion
Safe patient care requires safety-conscious individuals at the 
frontline to promote effective reporting and learning systems, 
to develop systems that facilitate information sharing about 
the number, types, causes, and consequences of errors, facili-
tate research in order to have a better understanding of the 
extent and causes of possible patient harm, and to develop 
appropriate solutions.17 Prescribing errors are a universal 
problem with similar potential impact on patients’ safety 
and quality of care.
To be most effective and better influence prescribing, 
pharmacists require clinical knowledge and a set of technical 
and social skills to underwrite competency so as to negotiate 
issues relating to best-practice in prescribing with clinicians. 
Our anecdotal experience suggests that pharmacists need to 
embed themselves authoritatively within the clinical team in 
order to develop a mutual respect. In such a relationship they 
might develop an understanding of the complex cognitive 
processes and emotions associated with clinician prescrib-
ing. In the clinical setting involved in this study, the senior 
clinical pharmacists complete the dual authoritative roles of 
Medical Pharmacy Advisor (MPA) to the regional Primary 
Health Care Team (PHCT) and as the Chairperson of the 
Drugs and Therapeutics sub-committee of the Corporate 
Clinical Governance Committee. We believe that pharmacists 
might achieve better acceptance of drug interventions by 
Table 3 Demographics of the patients who had prescriptions 
with errors
Criterion Statistic
Age 33.6 ± 13.3 years
Sex 478 males (80%)  
116 females (20%)
Average no of items per visit 3.6 ± 4.7
Table 4 Distribution of documented intervention across all clinics
Clinic Average daily 
prescriptions
Prescription over  
three months
Total no of interventions  
(% of total intervention*)
% Errors  
intercepted
A 150 10,800 203 (22%) 1.9
B 450 32,400 457 (53%) 1.5
c 280 20,160 155 (17%) 0.8
D 270 19,440 75 (8%) 0.4
Total 1150 82,800 890* 1.7Drug, Healthcare and Patient Safety 2009:1 77
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clinicians if they reference these interventions to previous, 
joint professional development sessions and to published 
literature that is normally resourced by clinicians such as 
American Family Physicians STEPS collection (freely 
accessible at: http://www.aafp.org/afp/steps).
This study provides an insight into the potential role of 
pharmacists in promoting rational drug use in Qatar. It also 
provided evidence of the magnitude of avoidable prescrib-
ing errors that pharmacists could intercept in outpatient 
pharmacies. The calculated figure of 1.7% prescriptions 
with an error is more than double that reported in the UK,13 
but it is significantly smaller than figures reported elsewhere 
(Sayer and colleagues,18 and Leemans and colleagues19) who 
reported 12.4% and 4.1% prescribing errors, respectively. 
However, several reasons for these differences in prevalence 
could be noticed, not the least in importance was the loca-
tion of the studies (community/private pharmacies versus 
pharmacies embedded within primary health care setting) 
and the fact that transcription errors, prescription legal issues 
and formulary issues were eliminated from our study through 
the full use of a CPOE, a factor which must have had huge 
impact on the number of intercepted errors.
Overall, drug choice problems and drug safety problems 
featured high in the list of prescribing errors identified. 
Considering the daily workload and the reality of the phar-
macists’ priorities (ie, serving patients comes before docu-
menting for the purpose of the study), we think the outcome 
in terms of documented interventions reported in these three 
months, while realistic, might be underestimating the real 
numbers of DRPs in the clinics involved. This could be due to 
documentation fatigue among the study pharmacists despite 
an effort to continuously keep motivating them to document 
each intervention they made. We have included interventions 
on the level of the patients in this analysis to have a feeling 
of the role that could be played by the pharmacist engaging 
in patient education when the need to do so was identified. 
In most of the cases involving patients, education materials 
were given out, along with counseling. These strategies are 
Safety
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Other Problem
5%
Drug Choice
Problem
53%
Figure 1 interventions:   All categories.
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expected to improve health outcomes and enhance patient 
compliance with drug therapy.
Interventions that were more likely to be accepted by 
the prescribing physicians were those involving dosage 
errors, duplicate therapy, and drug choice problems, in that 
order. We have not attempted to trace the fate of rejected 
interventions in this study. In the absence of a structured 
validation process we were unable to investigate the basis 
of rejected interventions. However, such an understanding 
is critical to the success of DRP intervention programs. 
Considering the large proportion of rejected interventions, 
it might be reasonable to assume that a percentage of those 
interventions made and rejected were actually correct and 
well-founded. We did not ascertain whether the intercepted 
prescriptions were dispensed despite suspected errors. 
If this is the case, then it might suggest an inability of the 
pharmacists concerned to engage into constructive dialogue 
with the prescribing physicians, despite having evidence that 
should have supported changing the therapy. Dispensing a 
prescription that could have an error raises significant ethical 
issues relating to the pharmacist’s Hippocratical obligation 
towards beneficence and nonmalfeasance (the responsibility 
to do good and the duty to do no harm). In general terms, 
dispensing a prescription that is suspected to be erroneous 
violates these basic ethical principles.
We found no association between the pharmacists’ char-
acteristics (ie, gender, age, and years of experience) and the 
number of interventions made or documented. This should 
not be surprising, since many other important factors might 
contribute to the ability of pharmacists to identify errors. 
These factors, such as the individual pharmacist’s motiva-
tion, interest, and clinical knowledge, are difficult to assess 
Wrong drug
8%
Not
administered
20%
Adverse drug
reaction
11% Drug interaction
9%
Dosing problem
52%
Figure 3 Safety category (Total 363).
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especially as they fall beyond the scope of the current project, 
while they could have significantly more influence than other 
demographics. We were unable to assess the association 
between errors identified (or accepted/rejected) with the 
clinician’s characteristics for logistical and ethical reasons.
The findings of this study should stimulate further 
research into the root cause for prescribing and medication 
errors. The results of such research should promote the devel-
opment of focused continuing education and training material 
that would specifically address gaps and safety risks in the 
prescribing process. This material should be delivered in 
ways that have been shown to improve prescribing behavior 
and should be extended to both physicians and pharmacists 
in a multidisciplinary environment.
Finally, it should be pointed out that no retrospective 
validation process was carried out by an independent 
reviewer on the interventions made or those rejected to 
ascertain grounds for rejection in this study. While accepted 
interventions carry an inherent validation by both the 
intervening pharmacist and the prescribing physician, the 
absence of validation targeting those interventions which 
were rejected by the prescribers remains a limitation in 
this study. Additionally, we have not made any attempt to 
classify the interventions beyond the PCNE classification 
system into broad DRP types. No classification based on 
potential ‘harm’ or seriousness of the prevented DRPs was 
made.
Conclusions
Documenting and analyzing interventions should be a routine 
activity in pharmacy practice of primary health care services. 
Progressive pharmacists are recognizing that this is only 
the first step in the process of improving patient safety. The 
real challenge is to work with clinicians to develop multiple 
1%
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Patient referred to prescriber
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Figure 5 intervention outcomes at patient levels (Total 270).
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channel interventions to better translate the exposure of 
clinicians to incontrovertible evidence into effect.20
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